Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Bristol-Myers Squibb
Canadian Cancer Trials Group
SWOG Cancer Research Network
Regeneron Pharmaceuticals
Rigshospitalet, Denmark
RenJi Hospital
Cancer Research UK
Alpha Biopharma (Jiangsu) Co., Ltd.
SWOG Cancer Research Network
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Guangzhou Medical University
Laibin People's Hospital
Canadian Cancer Trials Group
Fudan University
University of California, San Francisco
University Hospital, Brest
Canadian Cancer Trials Group
University of Wisconsin, Madison
University College, London
Washington University School of Medicine
Guangdong Association of Clinical Trials
European Organisation for Research and Treatment of Cancer - EORTC
Kyunghee University Medical Center
NeuroVita Clinic
AHS Cancer Control Alberta
Synta Pharmaceuticals Corp.
National Taiwan University Hospital
The Miriam Hospital
Peking University Third Hospital
PIMERIndia
Transgene
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Auron Healthcare GmbH
Zhejiang Cancer Hospital
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
The University of Texas Health Science Center at San Antonio
Pierian Biosciences
Bioven Sdn. Bhd.
National Institute of Cancerología
Sanofi
University of British Columbia